- Home
- III vs SGMT Comparison
III vs SGMT Comparison
Compare III & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- III
- SGMT
- Stock Information
- Founded
- III 2006
- SGMT 2006
- Country
- III United States
- SGMT United States
- Employees
- III N/A
- SGMT N/A
- Industry
- III Professional Services
- SGMT
- Sector
- III Consumer Discretionary
- SGMT
- Exchange
- III Nasdaq
- SGMT Nasdaq
- Market Cap
- III 249.2M
- SGMT 238.7M
- IPO Year
- III 2007
- SGMT 2023
- Fundamental
- Price
- III $5.42
- SGMT $7.36
- Analyst Decision
- III Buy
- SGMT Strong Buy
- Analyst Count
- III 1
- SGMT 7
- Target Price
- III $5.50
- SGMT $26.57
- AVG Volume (30 Days)
- III 247.9K
- SGMT 521.5K
- Earning Date
- III 11-03-2025
- SGMT 11-12-2025
- Dividend Yield
- III 3.32%
- SGMT N/A
- EPS Growth
- III N/A
- SGMT N/A
- EPS
- III 0.16
- SGMT N/A
- Revenue
- III $240,201,000.00
- SGMT N/A
- Revenue This Year
- III N/A
- SGMT N/A
- Revenue Next Year
- III $4.84
- SGMT N/A
- P/E Ratio
- III $34.54
- SGMT N/A
- Revenue Growth
- III N/A
- SGMT N/A
- 52 Week Low
- III $2.95
- SGMT $1.73
- 52 Week High
- III $6.01
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- III 48.44
- SGMT 49.54
- Support Level
- III $5.18
- SGMT $7.19
- Resistance Level
- III $5.61
- SGMT $8.11
- Average True Range (ATR)
- III 0.22
- SGMT 0.53
- MACD
- III -0.05
- SGMT 0.04
- Stochastic Oscillator
- III 29.07
- SGMT 36.28
About III Information Services Group Inc.
Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.